相关实验视频

Updated: Jun 23, 2025

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

慢性肝病患者接种COVID-19疫苗的血清反应

Yu-Shan Huang¹, Szu-Min Hsieh¹, Feng-Chiao Tsai²

¹Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan.

Journal of the Formosan Medical Association = Taiwan yi zhi

|June 21, 2024

概括

在慢性肝病患者接种COVID-19疫苗后的抗体水平随着时间的推移显著下降. 额外的补充剂量对于维持这种脆弱人群的免疫力至关重要.

科学领域:

免疫学免疫学免疫学
肝病学肝病学是一种肝病学.
疫苗学疫苗学疫苗学

背景情况:

有限的纵向数据存在于慢性肝病 (CLD) 患者对COVID-19疫苗接种的抗体反应.
了解CLD患者的疫苗疗效至关重要,因为他们可能会增加对严重感染的敏感性.

研究的目的:

为了纵向分析抗SARS-CoV-2高峰IgG抗体反应,在患有CLD的患者接受三剂COVID-19疫苗接种计划后.
评估抗体标位的持久性和疫苗接种对这一特定患者群体的影响.

主要方法:

从2021年8月到2023年2月,对45名CLD患者的抗SARS-CoV-2峰值IgG标位的顺序测量.
分析包括接受两剂或三剂mRNACOVID-19疫苗 (BNT162b2或mRNA-1273) 的患者.
在第二剂和第三剂后的四周和24周计算了几何平均标位.

主要成果:

在第二次 (1313.16 vs. 198.42 BAU/mL) 和第三次 (3042.29 vs. 636.71 BAU/mL) 剂量后,抗体标位从四周显著下降到24周.
在有或没有显著肝纤维化的CLD患者之间没有观察到抗尖峰IgG标位的显著差异.
同源的mRNA主要增强疫苗接种产生了可比的抗体水平,无论纤维化状态.

结论:

患有CLD的患者在完成初始COVID-19疫苗接种系列后,抗尖峰IgG抗体水平显著下降.
这些发现强调需要考虑额外的补充疫苗接种,以维持CLD患者的足够免疫力.
对于免疫力低下的人群,如患有CLD的人群,对最佳疫苗接种策略的进一步研究是有必要的.

关键词:

抗体是一种抗体.在 COVID-19 疫情中,慢性肝病是一种慢性肝病.肝脏纤维化肝脏纤维化疫苗疫苗疫苗疫苗

更多相关视频

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

相关概念视频

Cross-reactivity

Cross-reactivity

Diseases of the Liver and Gallbladder

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...